{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:52:36Z","timestamp":1776088356632,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Neoadjuvant immunotherapy for mismatch repair-deficient\/microsatellite instability-high (dMMR\/MSI-H) colorectal cancer continues to accumulate compelling clinical evidence. This report presents the case of a 37-year-old female who presented with moderate anemia (hemoglobin: 69 g\/L) and was subsequently diagnosed with dMMR\/MSI-H descending colon cancer. Following nine cycles of cadonilimab, a novel PD-1\/CTLA-4 bispecific antibody, the patient achieved significant tumor regression and subsequent pathological complete response (pCR) after surgery, with a favorable safety profile observed throughout the treatment course. This case provides valuable clinical evidence supporting the efficacy and safety of cadonilimab in the neoadjuvant setting for dMMR\/MSI-H colorectal cancer.<\/jats:p>","DOI":"10.3389\/fonc.2025.1693932","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:30:03Z","timestamp":1767591003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant therapy with cadonilimab in a patient with MSI-H\/dMMR colorectal cancer: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Jingrui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","article-title":"Global cancer burden growing, amidst mounting need for services","volume":"45","year":"2024","journal-title":"SAUDI MED J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/cancers15041022","article-title":"Challenges and therapeutic opportunities in the dMMR\/MSI-H colorectal cancer landscape","volume":"15","author":"Mulet-Margalef","year":"2023","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795972","article-title":"Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: New strategies and unveiled opportunities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1886077","article-title":"Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient\/microsatellite stability-high colorectal cancer and shedding light on future approaches","volume":"15","author":"Tan","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant nivolumab and ipilimumab in locally advanced dMMR colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B6","article-title":"Neoadjuvant PD-1 inhibitor sintilimab in mismatch repair-deficient or microsatellite instability-high colorectal cancer: a phase 2, single-arm trial","volume":"29","author":"Deng","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"NAT MED"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2024.2350355","article-title":"Neoadjuvant envafolimab in a patient with MSI-H\/dMMR colon cancer: a case report and literature review","year":"2024","journal-title":"immunotherapy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"6349","journal-title":"Sci (2017)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"JCO2200046","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial","author":"Morton","year":"2023","journal-title":"Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00064-4","article-title":"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","article-title":"Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study","volume":"40","author":"Verschoor","year":"2022","journal-title":"Clin Oncol"},{"key":"B18","first-page":"LBA7","volume-title":"Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study","author":"Chalabi","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.0952","article-title":"Revised TN categorization for colon cancer based on national survival outcomes data","volume":"28","author":"Gunderson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0019","article-title":"on behalf of the Dutch Surgical Colorectal Audit group. Locally Advanced Colon Cancer: Evaluation of Current Clinical Practice and Treatment Outcomes at the Population Level","volume":"15","author":"Klaver","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603646","article-title":"Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: Implications for clinical trials","volume":"96","author":"Smith","year":"2007","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant nivolumab and ipilimumab in locally advanced dMMR colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1844247","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1693932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:58:19Z","timestamp":1776085099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1693932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1693932"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1693932","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1693932"}}